SUPPLEMENTARY INFORMATION

Sensitive Detection and Tracking of Spontaneous Metastases in Deep Tissues via a Genetically Encoded Magnetic Resonance Imaging Reporter

Nivin N. Nyström^{1,2}, Sean W. McRae^{1,3}, Francisco M. Martinez³, John J. Kelly³, Timothy J. Scholl^{1,3,4,5,#}, John A. Ronald^{*,1,3,6,#}

¹Department of Medical Biophysics, Western University, London, ON, Canada

²Department of Chemical Engineering, California Institute of Technology, Pasadena, CA, USA

³Imaging Laboratories, Robarts Research Institute, Western University, London, ON, Canada

⁴Department of Physics and Astronomy, Western University, London, ON, Canada

⁵Ontario Institute for Cancer Research, Toronto, ON, Canada

⁶Lawson Health Research Institute, London, ON, Canada

[#]These are co-senior authors.

*Correspondence can be addressed to T.J.S. (tscholl@robarts.ca) and J.A.R. (jronald@robarts.ca).

Reference	Genetic Construct	Field	Gd(III) Dose	Performance
Patrick et al.	Doxycycline-inducible	7T,	0.664 to 2	7.8-fold greater signals than
PNAS (2014)	Oatp1a1 lentivirus	9.4T	mmol/kg	control xenograft at highest dose
	transfer plasmid			of 2 mmol/kg
Wu et al.	Constitutively expressed	7T	~2 mmol/kg*	2.7-fold greater signals than
FASEB (2018)	Oatp1b3 lentivirus			control xenografts
	transfer plasmid			
Nyström et al.	Constitutively expressed	3T	0.1 mmol/kg	2.6-fold greater signals than
Invest Radiol	Oatp1a1 lentivirus			control tumors
(2019)	transfer plasmid			
Kelly et al. Sci	Constitutively expressed	3T	1.67 mmol/kg	2.9-fold greater signals than
Adv (2021)	Oatp1a1 CRISPR-Cas9			control xenografts
	knock-in			

Table S1. Summary of *Oatp1*-MRI *in vivo* imaging publications, with information on genetic construct design, field strength, and Gd-EOB-DTPA dose. *Calculated from a reported administration of 200 µl of 250 mM Gd-EOB-DTPA per mouse, assuming an average weight of 25 g per mouse.



OATP1B3 Structural Prediction

Figure S1. Predicted aligned error plot for OATP1B3, where expected position error for the aligned residue is assigned an expected position error (Ångströms) against the rest of the protein sequence. The transmembrane domains of OATP1B3 exhibit low expected position error (<5 Å) whereas high expected position error (>25 Å) is demonstrated at both termini, Extracellular Domain 2 (ECD2) and Cytoplasmic Domain 4 (CD4).



Figure S2. Transmission electron microscopy of Luc-1B3 cells incubated with 1 mM Gd-EOB-DTPA (appearing as black foci in TEM images, highlighted by yellow arrows) for 1 hour. Gd(III) is shown to be encapsulated in residual bodies, which are typically destined for exocytosis. Scale bar, 500 nm.

Glycosylation Sites	Phosphorylation Sites	Disulfide Bonds	Kazal 1-like
			Domain
134	293	$459 \leftrightarrow 489$	453-508*
145	295	$465 \leftrightarrow 485$	
151	683	$474 \leftrightarrow 506$	
445			
503			
516			

Table S2. Predicted post-translational regulatory positions of OATP1B3. N-linked glycosylation to asparagine residues, which has been correlated to promotion of transporter function (31). Phosphorylation of serine residues has been correlated to downregulation of transporter activity (29). Disulfide bonds within the Kazal-1 like domain are predicted to result in serine protease inhibitor activity.



Figure S3. Nuclear magnetic relaxation dispersion (NMRD) profiles of Gd-DTPA and Gd-EOB-DTPA measured at 37°C. NMRD data for fields <1 T were acquired using a fast field-cycling relaxometer and extended by an inversion-recovery measurement at 1.5T on a clinical MRI system. (Measurement uncertainty < 1%.)

Gd-EOB-DTPA Efflux in Mammalian Cells



Figure S4. R_1 relaxation rates of Luc-1B3 cells normalized to Luc-CTL cells (a.u.), measured at time, t following 90-minute incubation with 1.6 mM Gd-EOB-TPA and immediate wash with PBS. Measurements were acquired at 37°C, 10 minutes to 48 hours post-incubation. Error bars represent standard deviation. Some error bars are too small to represent on plot.



Figure S5. Pre-contrast and post-contrast (1.3-mmol/kg Gd-EOB-DTPA) *T*₁-weighted images acquired at 3T of a representative Luc-CTL mouse on day 12.



Figure S6. Correlation of 2D Radiance (p/s/cm²/sr) measured from primary tumors on Day 12 *versus* 3D MRI contrast-enhanced volume of the same primary tumors at the same timepoint.



Figure S7. Timeline of metastasis and imaging protocol. Mammary fat pad, MFP. Bioluminescence imaging, BLI. T_1 -weighted magnetic resonance imaging at 3T, MRI.

Mouse C

Mouse E





Figure S8. Bioluminescence images (BLI) and post-contrast (1.3 mmol/kg Gd-EOB-DTPA) T_1 -weighted images acquired at 3T of two mice, whereby detection of initial metastasis at the ipsilateral axillary lymph node was detected with MRI prior to detection with BLI.